LncRNA DiGeorge syndrome critical region gene 5: A crucial regulator in malignant tumors

Long non-coding RNA (lncRNA), a subgroup of ncRNA with a length of more than 200 nt without protein coding function, has been recognized by the academia for its mediating effects of dysregulated expression on the tumorigenesis and development of a variety of tumors. LncRNA DiGeorge syndrome critical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2021-09, Vol.141, p.111889-111889, Article 111889
Hauptverfasser: Xia, Haoming, Huang, Ziyue, Liu, Shuqiang, Zhao, Xudong, He, Risheng, Wang, Zhongrui, Shi, Wenguang, Chen, Wangming, Li, Zhizhou, Yu, Liang, Huang, Peng, Kang, Pengcheng, Su, Zhilei, Xu, Yi, Yam, Judy Wai Ping, Cui, Yunfu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Long non-coding RNA (lncRNA), a subgroup of ncRNA with a length of more than 200 nt without protein coding function, has been recognized by the academia for its mediating effects of dysregulated expression on the tumorigenesis and development of a variety of tumors. LncRNA DiGeorge syndrome critical region gene 5 (DGCR5), originally found to induce DiGeorge syndrome, has been confirmed to be extremely dysregulated in multiple tumors, which mediates the malignant phenotypes of hepatocellular carcinoma, pancreatic cancer, lung cancer, etc. through the regulation of Wnt/β-catenin, MEK/ERK1/2 and other cancerous signaling pathways as a molecular sponge. Researches on the cancerous derivation-related pathways involved in DGCR5 can provide potential molecular intervention targets for tumor precision treatment. Moreover, liquid biopsy based on the detection of DGCR5 in body fluids is also expected to provide a non-invasive evaluation method for the early diagnosis and prognostic evaluation of malignant tumors. •LncRNAs are potential regulatory sites for cell metabolism and cancerous derivation.•DGCR5 has been confirmed to be abnormally expressed in multiple malignant tumors.•DGCR5 regulates the malignant biological phenotypes of various tumors.•DGCR5 can be used as a potential target for early diagnosis and precise therapy of tumors.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2021.111889